Olema Pharmaceuticals (OLMA) Gains from Investment Securities (2020 - 2026)
Olema Pharmaceuticals (OLMA) reported Gains from Investment Securities of $134005.0 for Q1 2026, up 18.47% year-over-year from $113112.0 in Q1 2025, and down 97.17% quarter-over-quarter from $4.7 million in Q3 2025.
Olema Pharmaceuticals (OLMA) Gains from Investment Securities (2020 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has 7 years of Gains from Investment Securities data on file, last reported at $134005.0 in Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at $134005.0, up 18.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $134005.0 (up 18.47% YoY), and the FY2025 annual result was $14.4 million, up 27.1% from the prior year.
- Gains from Investment Securities slipped to $134005.0 in Q1 2026 per OLMA's latest filing, from $4.7 million in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $11.4 million in Q4 2024 and troughed at $106016.0 in Q1 2024.
- A 5-year average of $5.0 million and a median of $4.0 million in 2024 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2022 and 2024: Gains from Investment Securities surged 9401.7% in 2022, then plunged 98.92% in 2024.
- A 5-year view of Gains from Investment Securities shows it stood at $8.4 million in 2022, then climbed by 3.41% to $8.7 million in 2023, then soared by 30.94% to $11.4 million in 2024, then slumped by 58.25% to $4.7 million in 2025, then sank by 97.17% to $134005.0 in 2026.
- Business Quant data shows OLMA's Gains from Investment Securities at $134005.0 in Q1 2026, $4.7 million in Q3 2025, and $896000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Olema Pharmaceuticals | 1.01 Bn | 1.01 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 134,005.00 |
| Mar 31, 2026 | 134,005.00 |
| Sep 30, 2025 | 4.74 Mn |
| Sep 30, 2025 | 4.74 Mn |
| Jun 30, 2025 | 896,000.00 |
| Jun 30, 2025 | 896,000.00 |
| Mar 31, 2025 | 113,112.00 |
| Mar 31, 2025 | 113,112.00 |
| Dec 31, 2024 | 11.35 Mn |
| Dec 31, 2024 | 11.35 Mn |
| Sep 30, 2024 | 3.30 Mn |
| Sep 30, 2024 | 3.30 Mn |
| Jun 30, 2024 | 180,013.00 |
| Jun 30, 2024 | 180,013.00 |
| Mar 31, 2024 | 106,016.00 |
| Mar 31, 2024 | 106,016.00 |
| Dec 31, 2023 | 8.67 Mn |
| Dec 31, 2023 | 8.67 Mn |
| Sep 30, 2023 | 8.98 Mn |
| Sep 30, 2023 | 8.98 Mn |